Novartis amps up Symjepi launch to fill Pfizer's EpiPen supply gap

Novartis amps up Symjepi launch to fill Pfizer's EpiPen supply gap

Source: 
Fierce Pharma
snippet: 

Mylan and its EpiPen manufacturing partner Pfizer have had trouble keeping up with demand. That's not good news as the key back-to-school season nears—except, perhaps, for Novartis' Sandoz unit and its stepped-up rollout of rival epinephrine injector Symjepi.